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Abstract
Background: The prerequisite for the potential use of the bacterial toxin verotoxin-1 in the treatment of breast
cancer was investigated by first determining the expression of its receptor Gb3 (CD77) in clinical breast cancer
tissue specimens. We then examined the cytotoxicity and mechanism of apoptosis induction of Escherichia coli
verotoxin-1 (VT-1) in two human breast cancer cell lines.
Methods: Immunohistochemistry for Gb3 expression was performed on cryostat section from 25 breast cancer
specimens. The human breast cancer cell lines T47D and MCF-7 were screened for Gb3 expression by flow
cytometry. Fluorescein diacetate and LDH release was used to determine cell viability after VT-1 exposure.
Apoptosis was studied by measuring caspase activity and DNA-fragmentation. Signal transduction studies were
performed on T47D cells with immunoblotting.
Results: Gb3 expression was detected in the vascular endothelial cells of all tumours specimens, and in tumour
cells in 17 of the specimens. We found no associations between tumour cell Gb3-expression and age, tumour
size, TNM-classification, histological type, hormone receptor expression, or survival time. T47D cells strongly
expressed Gb3 and were sensitive to the cytotoxicity, caspase activation and DNA fragmentation by VT-1,
whereas MCF-7 cells with faint Gb3-expression were insensitive to VT-1. VT-1 (0.01 – 5 μg/L) exposure for 72
h resulted in a small percentage of viable T47D cells whereas the cytotoxicity of cells pre-treated with 2 μmol/L
D, L-treo-1-phenyl-2-palmitoylamino-3-morpholino-1-propanol (PPMP, an inhibitor of glucosylceramide
synthesis) was eliminated (≤ 0.1 μg/L VT-1) or reduced (0.5 – 5 μg/L VT-1). VT-1 did not cause cellular LDH-
release or cell cycle arrest. VT-1 induction of caspase-3 (0.1, 1, and 5 μg/L VT-1), -8, and -9 (1 and 5 μg/L VT-1)
activity and DNA fragmentation of T47D cells was blocked by PPMP. Key components of MAP kinase signalling
pathways that control mitochondrial function were investigated. VT-1 0.1 – 5 μg/L induced phosphorylation of
JNK as well as MKK3/6 suggesting that survival signal pathways were overruled by VT-1-induced JNK activation
leading to mitochondrial depolarization, caspase-9 activation and apoptosis.
Conclusion: The high specificity and apoptosis-inducing properties of verotoxin-1 indicates that the toxin
potentially may be used for treatment of Gb3-expressing breast cancer.
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Background
Breast cancer is the most common malignancy affecting
women in the Western world. Systemic chemotherapy is
indicated for women with metastatic breast cancer (MBC)
[1]. Several single-agent and combination chemothera-
peutic options have been shown to be effective as first- or
second-line therapy in the management of MBC with the
taxanes and anthracyclines being the most active drugs
[2], however often with substantial side effects. An impor-
tant area of cancer research is the search for new effective
agents for targeted treatment with as small side effects as
possible. Apoptosis, the well-regulated intrinsic suicide
program that enables removal of unwanted cells is known
to be disabled in many tumour cells and identifying
agents that can overcome resistance to apoptosis could
greatly improve current chemotherapy options [3,4].
Bacterial toxins such as AC-toxin, botulinum toxin, chol-
era toxin, and verotoxin have been suggested to be used as
an approach to establish novel therapeutic agents against
tumour malignancies either as independent anti-neoplas-
tic agents or in combination treatment with chemo- or
radiotherapy. Toxins effective against specific signalling
pathways could reduce treatment side-effects to normal
tissues and be an approach to generate specific anti-
tumour agents [5]. VT-1 is a member of the bacterial shi-
gatoxin family expressed by some bacterial serotypes of
Escherichia coli, and Shigella dysenteriae. Verotoxin-1
induces cytotoxicity, apoptosis, and cell cycle arrest in
human tumour cells and has been suggested to be an anti-
cancer agent candidate due to its low general toxicity and
high specificity against tumours expressing its receptor,
globotriasosylceramide (Gb3) [6].
Gb3 (CD77) has been reported to be increased on the sur-
face of several tumour cells lines originating from breast
cancer, ovarian cancer, haematological malignancies, and
astrocytoma tumours as well as normal epithelial cells
[7,8]. The targeting of the toxin to a specific intracellular
transport pathway is determined by the Gb3 isoform
expressed on the cell surface and by the presence or
absence of Gb3 in the lipid raft microdomains of the cell
membrane [9].
The purpose of this study was to investigate the potential
of verotoxin-1 as a novel agent for enhancing apoptosis in
breast cancer cells by examining the expression of the
verotoxin-1 receptor Gb3 in breast cancer tissue followed
by elucidation of the specific signalling pathways to cellu-
lar proliferation and apoptosis. We investigated the cyto-
toxicity and induction of apoptosis as well as the signal
transduction mechanisms to apoptosis of Escherichia coli
verotoxin-1 in human breast cancer cell lines. We demon-
strate that verotoxin-1 has the potential to be an effective
anticancer drug in Gb3-expressing breast cancer.
Methods
Breast cancer patients
Tumour specimens were collected in the northern health-
care region of Sweden between 1985 and 1989 from 25
unselected women with primary invasive breast carci-
noma (11 node-negative and 14 node-positive patients)
all with snap-frozen tumour tissue available. Node-nega-
tive patients were generally treated with a modified radical
mastectomy or conservative surgery, followed by radio-
therapy. All node-positive patients were treated with sur-
gery and radiotherapy. Adjuvant systemic treatment was
administered to all node-positive patients. Most postmen-
opausal patients also received adjuvant endocrine ther-
apy. Prognostic and biological information were available
for all patients regarding TNM-classification, histological
type, oestrogen receptor (ER), progesterone receptor
(PgR), and survival time. The median age was 64 years
(range 34–83 years) and the median follow-up time was
63 months (last follow-up date was 30 June 1998). Sam-
ples was collected before informed consent became man-
datory, the study was approved (Dnr 02-455) by the ethics
committee of Umeå University.
Gb3 immunohistochemistry
Cryostat sections from biopsies of the breast cancer
tumours were cut and post-fixed in acetone. Gb3 immu-
nohistochemistry was performed with a monoclonal rat
IgM antibody at a dilution of 1:40 using the Envision sys-
tem (Dako, Denmark) and the staining evaluated by an
experienced pathologist (TB).
Cell lines and cell culture conditions
Two human breast cancer cell lines T47D and MCF-7 were
used. The cells were maintained under standard cell cul-
ture conditions, grown as monolayer culture in Eagle's
MEM with Earl's salt supplemented by 10% foetal bovine
serum and 200 μmol/L L-glutamine. They were incubated
at 37°C in a humidified atmosphere containing 5% CO2.
Determination and inhibition of Gb3-expression of 
cultured cells
T47D and MCF-7 cells were screened for expression of
Gb3 (CD77), the receptor for VT-1. Cellular expression of
Gb3 was identified by a monoclonal rat IgM antibody on
a FACSCalibur flow cytometer (Becton Dickinson Immu-
nocytometry Systems, San Jose, CA). DL-threo-1-phenyl-2-
palmitoylamino- 3-morpholino-1-propanol (PPMP) a
chemical inhibitor of glucosylceramide synthesis was
used to quench Gb3 expression. Cells were cultured with
2 μmol/L PPMP for 72 h prior to Gb3 expression analysis.
Cell viability assays
A fluorometric method utilising fluorescein diacetate
(FDA) was used to quantify cell viability and determine
VT-1 sensitivity of T47D and MCF-7 cells in vitro [10].BMC Cancer 2009, 9:67 http://www.biomedcentral.com/1471-2407/9/67
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Cells (1 × 104) were cultured and incubated with VT-1
(0.1 – 5 μg/L) followed by fluorescence determination as
described earlier [11]. The same procedure was made with
cells pre-treated with 2 μmol/L PPMP for 72 h prior to VT-
1 exposure, in which case 2 μmol/L PPMP was present in
the medium during the whole VT-1 incubation.
A colorimetric assay (Cytotoxicity detection kit, LDH
Roche Applied Science, Mannheim, Germany) was used
as described earlier [12] to measure lactate dehydrogenase
(LDH) release following cell membrane damages not seen
in apoptotic cells [13] to quantify necrosis induction by
VT-1 (0.1 – 5 μg/L) after 6 h.
Cell cycle analysis with propidium iodide staining 
measured by flow cytometry
Propidium iodide (PI) is a fluorescence dye that binds
specifically to double-stranded nucleic acids [14,15]. In
the flow cytometry assay employed, PI fluorescence is
indicative of the DNA content of the cells. Cells in the G2/
M phase are preparing to divide and they contain double
amount of DNA (4n) compared to cells in the G1 phase
that have not yet replicated their DNA (2n DNA content).
Upon completion of 72 h incubation with/without 0.01,
0.1 or 1 μg/L VT-1, the cell cultures were washed with PBS
and treated with 0.1% trypsin at 37°C. The cell suspen-
sion was collected, washed once with PBS (200 g, 5 min),
and re-suspended in PBS containing 70% cold absolute
ethanol, for fixation and permeabilisation of the cell
membrane (1 h, 4°C). After fixation the cells were washed
twice with PBS (900 g, 5 min), and the cells were treated
with 40 μg/mL RNase in PBS (final volume 100 μL), for
15 min at 37°C. Finally, the PI staining solution (50 μg/
mL PI and 3.8 mmol/L sodium citrate in PBS) was added
to the cells, followed by 3 h incubation in the dark, at
4°C. The cell cycle analysis was performed by a Fluores-
cence Activated Cell Sorter (FACSCalibur, Becton Dickin-
son, San Jose CA USA), and PI fluorescence (designated as
FL-2 Height in the histogram plots) was measured at 488
nm. Ten thousand cells were analyzed in each experiment.
The percentage of cells in the G2/M phase of the cell cycle
was then determined. The same procedure was used on
cells pre-treated with 2 μmol/L PPMP for 72 h before VT-
1 treatment.
DNA fragmentation analysis
TUNEL (TdT-mediated dUTP nick end labelling) staining
detecting nuclear DNA fragmentation was used as a
marker for late stage apoptosis using Roche's In situ cell
death detection kit, TMR red (Roche Applied Science,
Mannheim, Germany). T47D and MCF-7 cells were cul-
tured to about 80% confluence. Medium was thereafter
changed to fresh medium containing 0–5 μg/L VT-1 and
incubation continued for 72 h. Cells were thereafter har-
vested with trypsin and any floating cells collected by cen-
trifugation. Followed by TUNEL-stained according to the
manufactures instructions and TUNEL-staining was deter-
mined with flow cytometry. The same procedure was used
on cells pre-treated with 2 μmol/L PPMP for 72 h before
VT-1 treatment.
Caspase activity determination
Fluorometric assays were used to detect caspase -3, -8, and
-9 enzyme activities. T47D and MCF-7 cells were treated
with 0–5 μg/L VT-1 for 24 h. Thereafter caspase-enzyme
activity was measured with fluorometric assays (R&D Sys-
tems Inc., Minneapolis, MN, USA) as earlier described
[12]. The same procedure was used on cells pre-treated
with 2 μmol/L PPMP for 24 h before VT-1 treatment.
SDS-PAGE gel electrophoresis and immunoblotting
VT-1 influence on specific proteins involved in apoptosis
signal transduction was investigated through Western
blotting. Cells were exposed to 0.1, 1, 5 μg/L VT-1, and 5
μg/L VT-1 with 2 μmol/L PPMP for 24 h and then lysed in
lysis buffer. Gel electrophoresis and immunoblotting was
preformed as earlier described [11] using primary anti-
bodies against AKT, p-Aktser473, p-Akttyr308, Bad, p-
Badser112, p-Badser136, Bax, Bcl-2, p-Bcl-2ser70, Bcl-XL, SAPK/
JNK, p-SAPK/JNK, P44/42, p-P44/42 (ERK1/2), MKK 3/6,
p-MKK 3/6 and Monoclonal β-Actin antibody for detec-
tion of actin as loading control.
Reagents
Antibodies were obtained from the following: rat mono-
clonal IgM for Gb3 expression were from Immunotech,
Marseille, France and all other antibodies were from Cell
Signalling Technology Inc. Danvers, MA, USA. Eagle's
MEM in Earl's salt was from Gibco Ltd, Paisley, Scotland,
UK, and foetal bovine serum and L-glutamine were from
Biochrom KG, Berlin, Germany. Trypsin. DL-threo-1-phe-
nyl-2-palmitoylamino- 3-morpholino-1-propanol
(PPMP), fluorescein diacetate (FDA), verotoxin-1, propid-
ium iodide (PI), and RNase were from Sigma-Aldrich, St.
Louis, MO, USA. Lysis buffer were from R&D Systems Inc.
Minneapolis, MN, USA. The bicinchoninic acid (BCA)
protein assay kit was from Pierce Biotechnology Inc. Rock-
ford, IL, USA. NuPAGE antioxidant and reducing agent
were from Invitrogen, Carlsbad, CA, USA. Tris-HCl SDS-
PAGE criterion precast gel and Immune-Blot PVDF mem-
branes were from Bio-Rad, Hercules, CA, USA. ECL
Advance Western blotting detection system were from
Amersham Biosciences, Buckinghamshire, UK.
Statistics
Statistical significance was tested with one-way ANOVA.
The level of significance for rejecting the null hypothesis
of zero treatment effect was taken to be p = 0.05.BMC Cancer 2009, 9:67 http://www.biomedcentral.com/1471-2407/9/67
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Results
Immunohistochemical expression of Gb3 in breast cancer 
surgical specimens and patient outcome
Immunohistochemistry of cryostat sections of 25 breast
cancers demonstrated Gb3 expression in some arterioles
and small arteries in all specimens, whereas Gb3 expres-
sion was found in some tumour cells of 17 breast cancer
specimens. The vascular Gb3 staining was granular and
mainly confined to the endothelium but also seen in the
media of larger arterioles and small arteries. Fig. 1A–C
illustrates the immunohistochemical staining of two duc-
tal type breast cancer specimen with Gb3 expression in
tumour cell expression and endothelial staining in a small
arteriole. Fig 1D illustrates the granular Gb3 staining
found in the vessel wall of a small artery. There were no
apparent associations between tumour cell expression of
Gb3 and lymph-node status, tumour size, TNM-classifica-
tion, histological type or hormone receptor expression at
the time of diagnosis (Table 1) nor death of disease, or
survival time (not shown). A total of 16 deaths were
recorded during the follow-up time.
Gb3 expression of cultured breast cancer cells after 
verotoxin-1 exposure with/without PPMP inhibition
We then determined the expression of Gb3 in the human
breast cancer cell lines T47D and MCF-7. High Gb3
expression was observed on the surface of T47D whereas
Gb3 was only weakly expressed by MCF-7 cells (Fig. 2).
Culturing of T47D cells in the presence of 2 μmol/L PPMP
for 72 h, lead to a marked inhibition of Gb3 expression.
Verotoxin-1 cytotoxicity and cell cycle arrest
When incubated with 0.01 – 5 μg/L VT-1 for 72 h, the
number of viable T47D cells with high expression of Gb3
were very sensitive to VT-1 and the number of surviving
cells low even at 0.01 μg/L VT-1 (Fig. 3). When pre-incu-
Micrographs of immunohistochemistry on two breast cancer cryostat sections showing immunoreactivity of Gb3 (redbrown),  in (A-C) tumour cells and (D) vascular vessels Figure 1
Micrographs of immunohistochemistry on two breast cancer cryostat sections showing immunoreactivity of 
Gb3 (redbrown), in (A-C) tumour cells and (D) vascular vessels. 40× magnification.BMC Cancer 2009, 9:67 http://www.biomedcentral.com/1471-2407/9/67
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bated with PPMP for 72 h, full protection against VT-1
cytotoxicity was noted at 0.01 μg/L VT-1 whereas PPMP
protection at 0.1, 1 and 5 μg/L VT-1 was reduced with
increasing toxin concentration. On the other hand, VT-1
failed to induce cytotoxicity on the MCF-7 cell line with
low expression of Gb3 at a concentration as high as 5 μg/
L VT-1 (Fig. 3). Involvement of cytotoxicity by cell mem-
brane disruption was investigated by analyzes of LDH-
release after 6 h of VT-1 treatment. VT-1 (up to 5 μg/L) did
not increase LDH-release in T47D cells (data not shown).
Cell cycle analysis with propidium iodide staining for 24,
48 or 72 h demonstrated no effect of VT-1 on the distribu-
tion of cells in different cell cycle phases compared to
untreated control (data not shown).
Verotoxin-1 induction of DNA-fragmentation
DNA-fragmentation as marked by TUNEL-staining
increased in T47D cells when they were incubated with 0,
0.1, 1, or 5 μg/L VT-1 for 72 h. Pre-incubation with 2
μmol/L PPMP for 72 h completely inhibited TUNEL-
staining of T47D cells induced by incubation with 5 μg/L
VT-1 (Fig. 4).
VT-1 induction of caspase activity in T47D cells
To elucidate the signal transduction pathways of VT-1-
induced apoptosis, the induction of caspase-3, -8, and -9
enzyme activity was examined. Caspase-3 enzyme activity
increased when T47D cells were incubated with 0.1, 1 and
5  μg/L VT-1, and caspase-8, and -9 enzyme activity
increased when the were incubated with 1 and 5 μg/L VT-
1 for 24 h. When pre-incubated with 2 μmol/L PPMP for
24 h, all caspase enzyme activity was eradicated even with
cells incubated with 5 μg/L VT-1 (Fig. 5).
Immunoblot analysis
Western blot analysis was performed in an attempt to
identify involvement of pro- and anti-apoptotic proteins
(Akt, p-Aktser473, p-Akttyr308, Bad, p-Badser112, p-Badser136,
Bax, BCL-2, p-Bcl-2ser70, Bcl-XL, SAPK/JNK, p-SAPK/JNK,
P44/42, p-P44/42 (ERK1/2), MKK 3/6, p-MKK 3/6)
upstream of caspase-3. T47D cells were incubated with 0,
0.1, 1, 5 μg/L of VT-1, and 5 μg/L VT-1 with 2 μmol/L
PPMP for 24 h. SAPK/JNK (stress activated protein kinase/
c-JUN N-terminal Kinase), Bad, MKK3/6, and Akt were
uniformly expressed with no expression differences
regardless of treatment. The similar consistent pattern of
expression was noted for phosphorylated Akt at threonine
308 and serine 473. The active form of SAPK/JNK (p-
SAPK/JNK) was expressed at phosphorylation-sites threo-
nine 183 and tyrosine 185 in cells incubated with 0.1, 1,
and 5 μg/L of VT-1 but not in control cells, nor in cells pre-
treated with PPMP for 72 h (Fig. 6). The same expression
pattern was detected for phosphorylated MKK 3 and 6, at
serine 189 and threonine 193 for MKK3, and serine 207
and threonine 211 for MKK6. Phosphorylation of Bad at
serine 112 and 136 was constitutively expressed regardless
of VT-1 concentrations. Bax, Bcl-2, Bcl-XL, ERK1 and 2
(p44/42 MAP kinase) showed no changes from VT-1 treat-
ment (data not shown).
Discussion
The use of toxins targeted against specific tumour cells or
signal transduction pathways could reduce cancer treat-
ment side effects and toxicity to normal tissues and thus
be an approach to generate specific antitumour effects
[16]. Our results demonstrate that verotoxin-1- (VT-1)
induced cytotoxicity involves induction of apoptosis in
breast cancer cells expressing the toxin receptor Gb3. Gb3
Table 1: Clinicopathological characteristics of the patients
Feature With Gb3-expressing tumor cells (total number)
Patients 17 (25)
Lymph-node status
Node-negative 7 (11)
Node-positive 10 (14)
Histological type
Ductal 12 (16)
Lobular 1 (2)
Papillary 1 (2)
Medullary 1 (1)
Mixed 2 (4)
Tumor size
T1 5 (8)
T2 10 (13)
Clinicopathological characteristics of 25 breast cancer patientsBMC Cancer 2009, 9:67 http://www.biomedcentral.com/1471-2407/9/67
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expressing T47D cells were highly sensitive to VT-1 in vitro,
In contrast, the MCF-7 cells lacking Gb3 were completely
resistant to VT-1 treatment. Moreover, using PPMP, that
inhibits glucosylceramide synthesis and thus makes
exposed cells unable to synthesize Gb3 [17] rendered
T47D cells resistant or partly resistant to VT-1 depending
on toxin concentration.
We also demonstrated that VT-1 at higher concentrations
induces the intrinsic pathway to apoptosis, probably
through activation of JNK. This leads to disruption of the
mitochondrial membrane potential, activation of cas-
pase-9 and -3, ultimately leading to DNA fragmentation
and cell death. At higher VT-1 concentrations the mode of
cell death was still through Gb3-dependent apoptosis.
This was indicated by complete PPMP-blockable VT-1-
induced MAP kinase protein expression, caspase activities
and DNA fragmentation.
Most chemotherapeutic drugs exert their action by induc-
ing apoptosis and the development of resistance to chem-
otherapy appears to be mediated by alterations in the
sensitivity towards apoptosis [18,19]. Progress of tumour
growth and resistance to treatment is associated with
decreased rate of apoptosis [20]. Many cytotoxic agents
have a relatively narrow therapeutic window and in many
patients the risk of side effects are higher than the proba-
bility of obtaining a clinical benefit. Targeted toxins
against specific pathways could reduce the toxicity to non-
tumour cells and be an approach to generate specific anti-
tumour agents.
Several reports have demonstrated that VT-1 induces
apoptosis in solid tumour cell lines such as astrocytoma,
renal cell carcinoma, and colon cancer [21-23]. VT-1 has
also been shown to induce apoptosis and rapid elimina-
tion of mice tumour xenografts in Gb3-expressing human
renal cell carcinoma, colon carcinoma, bladder carci-
noma, glioblastoma, malignant meningiomas [23-27].
Furthermore, 80% of all primary and metastatic breast
cancer biopsies have been shown to express Gb3 [8]. A
recent study demonstrated expression of Gb3 in meta-
Gb3 expression of T47D and MCF-7 cells with/without 72 h  pre-treatment with 2 μmol/L PPMP Figure 2
Gb3 expression of T47D and MCF-7 cells with/with-
out 72 h pre-treatment with 2 μmol/L PPMP. Control 
is with secondary antibody only.
Viability dose-response of T47D cells (filled circles), PPMP- pre-treated T47D cells (open circles), and MCF-1 cells (trian- gles), after 72 h of exposure to verotoxin-1 at indicated con- centrations 100% cell viability is untreated cells cultured  under for 72 h Figure 3
Viability dose-response of T47D cells (filled circles), 
PPMP-pre-treated T47D cells (open circles), and 
MCF-1 cells (triangles), after 72 h of exposure to 
verotoxin-1 at indicated concentrations 100% cell via-
bility is untreated cells cultured under for 72 h. Data 
denote mean values ± SD for 6 or 12 separate observations.BMC Cancer 2009, 9:67 http://www.biomedcentral.com/1471-2407/9/67
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static colon cancer, whereas expression was virtually
absent in normal colonic epithelial cells [26]. Elevated
expression of Gb3 has also been demonstrated in drug-
resistant ovarian tumours compared to the primary
tumour [28]. Gb3 has also shown to co-localize with the
multi drug resistance protein P-glycoprotein (Pgp/MDR1)
and have thus been suggested as a possible target for multi
drug resistant cells [29]. We recently demonstrated Gb3 in
vascular endothelial- and tumour cells by immunostain-
ing of Gb3 expression in glioma cryostat sections. The
present results of the immunostaining showed expression
of Gb3 in endothelial cells but also in tumour cells. This
suggests that VT-1 exposure could be effective directly
against breast cancer tumour cells but also affect tumour
vascularity as suggested also for gliomas [30]. The present
demonstration of Gb3 expression in breast cancer tissue
indicates that it is possible to use VT-1 also in the treat-
ment of breast cancer. Further investigations should, how-
ever, be conducted to ensure that the cytotoxic effect of
VT-1 does not lead to severe adverse effects due to target-
ing of normal Gb3-expressing cells outside of the tumor.
The most important target expressing high levels of Gb3
would be the microvasculature of the kidney. It is also the
main target of E. Coli VT-1-induced haemolytic uraemic
syndrome [31] Other non-tumour target cells of concern
for adverse effects would be tonsil germinal-center B lym-
phocytes which regularly express Gb3 [32]. Finding safe
Percentage of TUNEL-stained T47D cells after 72 h expo- sure to 0, 0.1, 1, or 5 μg/L verotoxin-1 and μg/L verotoxin-1  with 2 μmol/L PPMP Mean ± SD of three separate observa- tions Figure 4
Percentage of TUNEL-stained T47D cells after 72 h 
exposure to 0, 0.1, 1, or 5 μg/L verotoxin-1 and μg/L 
verotoxin-1 with 2 μmol/L PPMP Mean ± SD of three 
separate observations.
Relative caspase-3, -8 and -9 enzyme activities of T47D cells  incubated for 24 h with verotoxin-1 with or without 2 μmol/ L PPMP compared to untreated control (activity set to 1) Figure 5
Relative caspase-3, -8 and -9 enzyme activities of 
T47D cells incubated for 24 h with verotoxin-1 with 
or without 2 μmol/L PPMP compared to untreated 
control (activity set to 1). Significant differences (p < 
0.05) compared to untreated control are marked with *.
Effect of verotoxin-1 in T47D cells on the expression of the  total and phosphorylated MAP kinases JNK and MKK3/6  after 24 h exposure to verotoxin-1 with or without 2 μmol/L  PPMP Figure 6
Effect of verotoxin-1 in T47D cells on the expression 
of the total and phosphorylated MAP kinases JNK 
and MKK3/6 after 24 h exposure to verotoxin-1 with 
or without 2 μmol/L PPMP. β-Actin is shown as loading 
control.BMC Cancer 2009, 9:67 http://www.biomedcentral.com/1471-2407/9/67
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modes of administration are of critical importance for use
of VT-1 as an anti-neoplastic agent.
We demonstrated that VT-1 induced a dose-dependent
decrease of cell viability in Gb3-expressing T47D cells, but
not in MCF-7 cells which lacked Gb3 expression. Expres-
sion of the membrane receptor Gb3 is obviously required
for VT-1 internalization and transport of the toxin to the
endoplasmic reticulum [33]. When T47D cells were incu-
bated with PPMP, that inhibits glucosylceramide synthe-
sis and thus Gb3 expression [17], prior to VT-1 exposure
the sensitivity to VT-1 cytotoxicity at lower toxin concen-
trations was lost.
We then studied if VT-1-induced cytotoxicity was due to
induction of apoptosis. Massive VT-1-induced DNA-frag-
mentation as well as apoptosis-related morphological
changes was detected in the Gb3-expressing cell line T47D
after 72 h incubation with high concentrations of VT-1.
Pre-treatment with PPMP for 72 h prior to VT-1 exposure
completely abolished VT-1-incuded DNA fragmentation.
Apoptosis is most often executed by the activation of cas-
pase -3. Activation of caspase-3 can be achieved either by
caspase-8, the most proximal caspase in the receptor sig-
nalling pathway or by caspase-9 in the mitochondrial
pathway to apoptosis. We therefore examined the activa-
tion of the three caspases after 24 h VT-1 exposure. Cas-
pases-3 and -9, but not caspase-8 was found to be
activated in both cell lines indicating that the intrinsic
pathway to apoptosis was activated by VT-1. There was no
VT-1-induced cellular activation of caspase-3,-8, or -9 after
pre-incubation with PPMP. The mode of VT-1 cytotoxicity
at low concentrations is still unclear. Nevertheless, cyto-
toxicity is apparently dependent on the cellular expression
of Gb3 but not due to apoptosis, necrosis or cell cycle
arrest as noted by lack of caspase activity or DNA fragmen-
tation, cell lysis, and changes in cell cycle distribution,
respectively.
Protein phosphorylation is the major cellular mechanism
used to regulate protein functions, among them control-
ling cell growth, death, differentiation and apoptosis. The
phosphorylation state of the key components of MAPK
signalling pathways [34] controlling Bax and mitochon-
drial function related to cell survival and apoptosis was
therefore investigated. VT-1 induced JNK and MKK3/6
phosphorylation in T47D cells, suggesting that survival
signal pathways were overruled by VT-1-induced JNK and
p38 activation leading to mitochondrial depolarization,
caspase-9 activation and apoptosis. Similar increases of
JNK phosphorylation leading to apoptosis have been
demonstrated to be essential for Pseudomonas aeruginosa
ExoS-induced apoptosis [35] and for verotoxin-1 in gli-
oma cell lines [11].
Despite clinical improvements there are still major prob-
lems associated with breast cancer treatment. Chemother-
apy and radiotherapy are associated with many,
sometimes severe side effects. Therefore, targeted thera-
pies that effectively kill cancer cells, without affecting nor-
mal tissues is a major objective in clinical cancer research.
The high specificity and the ability of verotoxin-1 to selec-
tively induce breast cancer cell death indicate that vero-
toxin-1 may be used as a potential anti-neoplastic agent
for treatment of Gb3-positive breast cancers.
Conclusion
Despite clinical improvements there are still major prob-
lems associated with breast cancer treatment. Chemother-
apy and radiotherapy are associated with many,
sometimes severe side effects. Therefore, targeted thera-
pies that effectively kill cancer cells, without affecting nor-
mal tissues is a major objective in clinical cancer research.
The high specificity and the ability of verotoxin-1 to selec-
tively induce breast cancer cell death indicate that vero-
toxin-1 may be used as a potential anti-neoplastic agent
for treatment of Gb3-positive breast cancers.
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